Depakote Sprinkles Alternatives Compared
| Depakote Sprinkles (divalproex sodium) | Keppra (levetiracetam) | Levetiracetam |
|
|---|
| Depakote Sprinkles (divalproex sodium) | Keppra (levetiracetam) | Levetiracetam |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Seizures, Epilepsy. Depakote Sprinkles may also be used for purposes not listed in this medication guide. |
Prescription only
Keppra is an anticonvulsant that is used in conjunction with other medications for the treatment of certain types of seizures. It may cause drowsiness but it is less likely than some other... View more |
Prescription only
Levetiracetam is an anticonvulsant that is used in conjunction with other medications for the treatment of certain types of seizures. It may cause drowsiness but interactions with other medications... View more |
Related suggestions Seizures
|
|||||||||||||||||||||||
| More about Depakote Sprinkles (divalproex sodium) | More about Keppra (levetiracetam) | More about Levetiracetam | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Depakote Sprinkles has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Keppra has an average rating of 5.7 out of 10 from a total of 307 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 34% reported a negative effect. |
Levetiracetam has an average rating of 5.9 out of 10 from a total of 429 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 32% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Depakote Sprinkles side effects |
View all Keppra side effects |
View all Levetiracetam side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Lower cost generic approved |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Depakote Sprinkles prices |
View all Keppra prices |
View all Levetiracetam prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other divalproex sodium brands include: Depakote, Depakote ER | Other levetiracetam brands include: Elepsia XR, Keppra XR, Roweepra, Roweepra XR, Spritam | Elepsia XR, Keppra, Keppra XR, Roweepra, Roweepra XR, Spritam | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
16 hours |
8 hours |
8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
When Treating Epilepsy And Manic Episodes Associated With Bipolar Disorder
Category X
Not for use in pregnancy
When Treating Migraine See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 424 drugs are known to interact with Depakote Sprinkles:
|
A total of 238 drugs are known to interact with Keppra:
|
A total of 238 drugs are known to interact with Levetiracetam:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
November 30, 1999 |
November 30, 1999 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.